ClinicalTrials.gg
CompletedNCT00258700Updated Sep 21, 2016

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

A Phase 3 interventional study of Haemophilus influenzae type b- and meningococcal (vaccine) in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 10 sites in 2 countries. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
478
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
36th of 80
478 · median 445
Started
2005
with 6 others
Phase 3
48 of 82
none open now
Registered
10th of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 36th largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2005, is one of 48 in phase 3, and was the 10th registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to demonstrate the non-inferiority of the candidate Hib-MenC conjugate vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™ when given according to a 2, 3, 4 month schedule and the immunogenicity of the Hib-MenC vaccine when given as a booster dose at 12-15 months of age.

Read the detailed description

This multicenter study is open with respect to the treatment allocation, but double-blind with respect to the Hib-MenC-TT lots (3 lots). The study will be conducted in two stages. Primary vaccination phase: 3 doses Hib-MenC-TT with Infanrix™-IPV or for the control group a licensed Men-C vaccine with Pediacel™ at 2, 3, 4 months of age; Booster/persistence phase: 1 dose Hib-MenC with Priorix™. 4 blood samples of 3.5ml (5ml for the UK subset) are collected (Study Months 0 \& 3, prior to \& 42 days after the booster).

03

Conditions studied

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female, between, and including, 6 and 12 weeks of age.
  • Born after a gestation period between 36 and 42 weeks
  • Vaccination with at birth and at 6 to 12 weeks (concomitantly with the first study vaccine), accepted although not mandatory

Exclusion criteria

Exclusion criteria:

  • Planned administration/ administration of a vaccine not foreseen by the study protocol since birth, with the exception of Bacille Calmette Guerin (BCG) and vaccines.
  • History of H. influenzae type b and /or meningococcal serogroup C disease.
  • Previous vaccination against meningococcal serogroup C disease, diphtheria, tetanus, pertussis, polio or Hib disease.
  • Any confirmed or suspected or immunodeficient condition, including (HIV) infection
  • A family history of congenital or hereditary immunodeficiency
  • History of any neurologic disorders or seizures
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
478 participants (actual)

Interventions

  • BiologicalHaemophilus influenzae type b- and meningococcal (vaccine)
06

What researchers measure

Primary outcomes

  1. 1 m after the 3rd dose of primary vaccination: SBA-MenC titre ≥ 1:8 (seroprotection status), anti-PRP concentration ≥ 0.15 µg/ml. 42 d after the booster vaccination: SBA-MenC titre ≥ 1:128, anti-PRP concentration ≥ 1 μg/ml

Secondary outcomes

  1. Antibody levels to all vaccine antigens:1 m post dose 3, prior to & 42 d post booster. After each dose: Solicited (d 0-3, local & general), unsolicited (d 0-30) & MMR specific (d 0-42) symptoms. SAEs (whole study).

07

Study locations

10 sites
  • GSK Investigational Site
    Bydgoszcz, 85-021, Poland
  • GSK Investigational Site
    Gdansk, 80-394, Poland
  • GSK Investigational Site
    Kielce, 25-711, Poland
  • GSK Investigational Site
    Krakow, 31-202, Poland
  • GSK Investigational Site
    Leczna, 21-010, Poland
  • GSK Investigational Site
    Lodz, 91-347, Poland
  • GSK Investigational Site
    Poznan, 61-709, Poland
  • GSK Investigational Site
    Siemianowice Slaskie, 41-103, Poland
  • GSK Investigational Site
    Trzebnica, 55-100, Poland
  • GSK Investigational Site
    Oxford, Oxfordshire OX3 7LJ, United Kingdom
08

References and documents

Publications

  • Pace D, Snape M, Westcar S, Oluwalana C, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, Pollard AJ. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child. 2008 Nov;93(11):963-70. doi: 10.1136/adc.2007.136036. Epub 2008 May 7. PubMed 18463125 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2005
First posted
Nov 28, 2005
Start
Feb 2005
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Last update
Sep 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00258700
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 28, 2005
Start date
Feb 2005
Primary completion
Jul 2006
Completion
Jul 2006
Last update
Sep 21, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion